Developer docs
API playgroundTry for free, no card

Search company profiles

XenoSTART

Full company profile

uuid000eivw

Namestring
XenoSTART
Websiteurl
xenostart.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

XenoSTART is a nonclinical oncology contract research organization that operates the patient-derived xenograft (PDX) platform for pharmaceutical and biotechnology companies developing oncology therapeutics. Founded in 2007 and based in San Antonio, Texas, XenoSTART operates as a preclinical business unit of The START Center for Cancer Research, a parent organization with 100,000+ square feet of research facilities and a documented track record of contributing to FDA and EMA approved cancer therapies across 800+ completed and active studies.

The core offering is the PDX platform itself, in which patient-derived tumor tissue is implanted into immunocompromised mouse models to create patient avatars for oncology drug testing and translational research. Unlike conventional cell line models, PDX models preserve patient tumor heterogeneity and are positioned as more predictive of clinical response. The Minerva Imaging collaboration provides adjunct imaging capabilities for PDX studies. The primary customer segments are pharmaceutical and biotechnology companies with oncology drug pipelines requiring predictive preclinical models, served through a direct enterprise sales motion.

XenoSTART's revenue model is professional services: each engagement is a custom preclinical research project priced on study scope, with pricing not publicly disclosed. As a sub-unit of the START Center, it leverages the parent's established biopharma relationships and global research network spanning 8 locations across the United States and Europe (Spain, Portugal, Ireland). The company is led by Dr. Frank Smith, appointed President in February 2026, who was recruited from Champions Oncology, Charles River, and GSK to scale the PDX platform.

Short descriptiontext

XenoSTART is a nonclinical oncology CRO that provides patient-derived xenograft (PDX) model services to pharmaceutical and biotechnology companies developing oncology therapeutics, operating as a preclinical business unit of The START Center for Cancer Research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical oncology research, patient-derived xenograft models, translational cancer research, nonclinical CRO services, oncology drug development
Industry2 codes
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAOAJ
Preclinical, Toxicology & Translational Science Staffing FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Oncology CRO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Research Services
TypeProfessional Services
Description

XenoSTART provides preclinical research services to pharmaceutical and biotechnology companies through its PDX platform, enabling oncology drug developers to conduct translational research that accelerates the translation of preclinical insights into clinical development.

prnewswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

XenoSTART provides preclinical oncology research services through its proprietary Patient-Derived Xenograft (PDX) platform, in which patient-derived tumor tissue is implanted into immunocompromised mice to create patient avatars for drug testing. The service enables pharmaceutical and biotechnology companies to generate more clinically predictive preclinical data, supporting translational research that accelerates the path from preclinical insights to clinical development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

XenoSTART is a preclinical business unit of The START Center for Cancer Research that operates as a focused platform offering patient-derived xenograft (PDX) models for oncology drug developers. The core offering is the PDX Platform, which enables pharmaceutical companies to conduct translational research using patient-derived tumor models, supporting the acceleration of preclinical insights into clinical development.

Product and service1 record
1Patient-Derived Xenograft (PDX) Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

XenoSTART has a strategic collaboration with Minerva Imaging focused on Patient-Derived Xenograft (PDX) model development and services for oncology drug development. This collaboration enhances XenoSTART's capabilities in providing translational research solutions to pharmaceutical and biotechnology companies developing oncology therapeutics.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins is a global bioanalytical and preclinical testing services provider with a significant CRO footprint that includes preclinical and oncology research offerings. It competes with XenoSTART as a broad incumbent providing outsourced laboratory research services to biopharma.

TypeDirect peer
Description

Crown Bioscience is a global preclinical and translational CRO specializing in oncology models including a large PDX platform (HuPrime), serving pharma and biotech sponsors worldwide. Like XenoSTART, it focuses on patient-derived models for preclinical oncology drug development with global vivarium and imaging capabilities.

TypeBroad incumbent
Description

WuXi AppTec is a leading global CRO/CDMO offering preclinical oncology research services, including in vivo efficacy and PDX studies for biopharma sponsors. It competes with XenoSTART for outsourced preclinical oncology work at large scale, particularly with US and European biotech sponsors.

TypeEmerging player
Description

The Jackson Laboratory provides preclinical oncology research services, including patient-derived xenograft models and humanized mice, for academic and biopharma sponsors. It overlaps with XenoSTART in PDX-based translational research and is a relevant emerging player in the specialized preclinical oncology space.

TypeEmerging player
Description

Taconic Biosciences is a supplier of research models, including specialized oncology and humanized mouse models used for preclinical oncology studies. While not a full-service CRO, Taconic overlaps with XenoSTART in the underlying mouse model infrastructure that PDX programs rely on.

TypeEmerging player
Description

Reaction Biology offers preclinical and early discovery services including oncology-relevant assays and in vivo efficacy studies. It is an emerging/specialized provider that competes for outsourced preclinical oncology study budgets alongside XenoSTART.

TypeDirect peer
Description

Champions Oncology is a pure-play oncology preclinical CRO offering patient-derived xenograft (PDX) and ex vivo tumor platform services to biopharma. It is the most direct competitor to XenoSTART, serving the same oncology drug developers with the same PDX-based translational offering. Notably, XenoSTART's incoming president previously held a leadership role at Champions Oncology.

TypeBroad incumbent
Description

Labcorp (formerly Covance/Fortrea-adjacent) operates a large CRO business providing preclinical, clinical, and diagnostic services to biopharma, including oncology. It competes with XenoSTART for preclinical oncology work as a broad incumbent with global scale and a wider service portfolio.

TypeBroad incumbent
Description

Charles River Laboratories is one of the largest preclinical CROs globally, offering end-to-end discovery, safety assessment, and vivarium services including oncology PDX models. It is both a direct competitor in preclinical oncology and a benchmark large incumbent that XenoSTART's incoming president previously worked at.

TypeDirect peer
Description

MI Bioresearch is a preclinical CRO focused on in vivo oncology studies and patient-derived xenograft models for biopharma clients. It is a comparable specialized PDX/preclinical oncology provider competing directly with XenoSTART for sponsor outsourced studies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

XenoSTART

Preclinical Oncology CRO Servicesxenostart.com

XenoSTART is a nonclinical oncology CRO that provides patient-derived xenograft (PDX) model services to pharmaceutical and biotechnology companies developing oncology therapeutics, operating as a preclinical business unit of The START Center for Cancer Research.

What XenoSTART does

XenoSTART is a nonclinical oncology contract research organization that operates the patient-derived xenograft (PDX) platform for pharmaceutical and biotechnology companies developing oncology therapeutics. Founded in 2007 and based in San Antonio, Texas, XenoSTART operates as a preclinical business unit of The START Center for Cancer Research, a parent organization with 100,000+ square feet of research facilities and a documented track record of contributing to FDA and EMA approved cancer therapies across 800+ completed and active studies.

The core offering is the PDX platform itself, in which patient-derived tumor tissue is implanted into immunocompromised mouse models to create patient avatars for oncology drug testing and translational research. Unlike conventional cell line models, PDX models preserve patient tumor heterogeneity and are positioned as more predictive of clinical response. The Minerva Imaging collaboration provides adjunct imaging capabilities for PDX studies. The primary customer segments are pharmaceutical and biotechnology companies with oncology drug pipelines requiring predictive preclinical models, served through a direct enterprise sales motion.

XenoSTART's revenue model is professional services: each engagement is a custom preclinical research project priced on study scope, with pricing not publicly disclosed. As a sub-unit of the START Center, it leverages the parent's established biopharma relationships and global research network spanning 8 locations across the United States and Europe (Spain, Portugal, Ireland). The company is led by Dr. Frank Smith, appointed President in February 2026, who was recruited from Champions Oncology, Charles River, and GSK to scale the PDX platform.

XenoSTART firmographics

Firmographics
Name
XenoSTART
Website
https://xenostart.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
XenoSTART is a nonclinical oncology CRO that provides patient-derived xenograft (PDX) model services to pharmaceutical and biotechnology companies developing oncology therapeutics, operating as a preclinical business unit of The START Center for Cancer Research.
Ownership category
akta.pro rank

XenoSTART industry classification

Industry
Product category
Preclinical Oncology CRO Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAOAJ
Preclinical, Toxicology & Translational Science Staffing FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Preclinical oncology research
  • Patient-derived xenograft models
  • Translational cancer research
  • Nonclinical CRO services
  • Oncology drug development

Where XenoSTART is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Offices1 record

Markets served

XenoSTART business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical Research Services: XenoSTART provides preclinical research services to pharmaceutical and biotechnology companies through its PDX platform, enabling oncology drug developers to conduct translational research that accelerates the translation of preclinical insights into clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

XenoSTART product offering

Product offering

Core offering

XenoSTART provides preclinical oncology research services through its proprietary Patient-Derived Xenograft (PDX) platform, in which patient-derived tumor tissue is implanted into immunocompromised mice to create patient avatars for drug testing. The service enables pharmaceutical and biotechnology companies to generate more clinically predictive preclinical data, supporting translational research that accelerates the path from preclinical insights to clinical development.

Product overview

XenoSTART is a preclinical business unit of The START Center for Cancer Research that operates as a focused platform offering patient-derived xenograft (PDX) models for oncology drug developers. The core offering is the PDX Platform, which enables pharmaceutical companies to conduct translational research using patient-derived tumor models, supporting the acceleration of preclinical insights into clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Patient-Derived Xenograft (PDX) Platform

Companies that use XenoSTART

Customer profile

Segments2 records

Ideal customer profiles2 records

XenoSTART technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

XenoSTART partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Minerva ImagingcoreStrategic or Co-development PartnerXenoSTART has a strategic collaboration with Minerva Imaging focused on Patient-Derived Xenograft (PDX) model development and services for oncology drug development. This collaboration enhances XenoSTART's capabilities in providing translational research solutions to pharmaceutical and biotechnology companies developing oncology therapeutics.

Scale indicators5 records

Recent moves3 records

Expansion highlights4 records

XenoSTART competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Eurofins is a global bioanalytical and preclinical testing services provider with a significant CRO footprint that includes preclinical and oncology research offerings. It competes with XenoSTART as a broad incumbent providing outsourced laboratory research services to biopharma.
  • WuXi AppTec: WuXi AppTec is a leading global CRO/CDMO offering preclinical oncology research services, including in vivo efficacy and PDX studies for biopharma sponsors. It competes with XenoSTART for outsourced preclinical oncology work at large scale, particularly with US and European biotech sponsors.
  • Labcorp Drug Development: Labcorp (formerly Covance/Fortrea-adjacent) operates a large CRO business providing preclinical, clinical, and diagnostic services to biopharma, including oncology. It competes with XenoSTART for preclinical oncology work as a broad incumbent with global scale and a wider service portfolio.
  • Charles River Laboratories: Charles River Laboratories is one of the largest preclinical CROs globally, offering end-to-end discovery, safety assessment, and vivarium services including oncology PDX models. It is both a direct competitor in preclinical oncology and a benchmark large incumbent that XenoSTART's incoming president previously worked at.

Direct peers

  • Crown Bioscience: Crown Bioscience is a global preclinical and translational CRO specializing in oncology models including a large PDX platform (HuPrime), serving pharma and biotech sponsors worldwide. Like XenoSTART, it focuses on patient-derived models for preclinical oncology drug development with global vivarium and imaging capabilities.
  • Champions Oncology: Champions Oncology is a pure-play oncology preclinical CRO offering patient-derived xenograft (PDX) and ex vivo tumor platform services to biopharma. It is the most direct competitor to XenoSTART, serving the same oncology drug developers with the same PDX-based translational offering. Notably, XenoSTART's incoming president previously held a leadership role at Champions Oncology.
  • MI Bioresearch: MI Bioresearch is a preclinical CRO focused on in vivo oncology studies and patient-derived xenograft models for biopharma clients. It is a comparable specialized PDX/preclinical oncology provider competing directly with XenoSTART for sponsor outsourced studies.

Emerging players

  • The Jackson Laboratory: The Jackson Laboratory provides preclinical oncology research services, including patient-derived xenograft models and humanized mice, for academic and biopharma sponsors. It overlaps with XenoSTART in PDX-based translational research and is a relevant emerging player in the specialized preclinical oncology space.
  • Taconic Biosciences: Taconic Biosciences is a supplier of research models, including specialized oncology and humanized mouse models used for preclinical oncology studies. While not a full-service CRO, Taconic overlaps with XenoSTART in the underlying mouse model infrastructure that PDX programs rely on.
  • Reaction Biology: Reaction Biology offers preclinical and early discovery services including oncology-relevant assays and in vivo efficacy studies. It is an emerging/specialized provider that competes for outsourced preclinical oncology study budgets alongside XenoSTART.

Market position

Strengths4 records

Weaknesses2 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

XenoSTART social profiles

Digital presence

XenoSTART financial estimates

Financial estimate

Revenue estimate

Valuation estimate

XenoSTART leadership team

Management profile

Number of profiles

Profiles1 record

XenoSTART funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

XenoSTART M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XenoSTART

What does XenoSTART do?

XenoSTART provides preclinical oncology research services through its proprietary Patient-Derived Xenograft (PDX) platform, in which patient-derived tumor tissue is implanted into immunocompromised mice to create patient avatars for drug testing. The service enables pharmaceutical and biotechnology companies to generate more clinically predictive preclinical data, supporting translational research that accelerates the path from preclinical insights to clinical development.

Is XenoSTART a public or private company?

XenoSTART is a private company. It is classified as corporate owned and is currently operating.

When was XenoSTART founded?

XenoSTART was founded in 2007. It employs 11 to 50 people.

Where is XenoSTART based?

XenoSTART is headquartered in San Antonio, United States, in the North America region.

How does XenoSTART make money?

One revenue line is on record: preclinical Research Services.

Who are XenoSTART's main competitors?

Broad incumbents on record are Eurofins Scientific, WuXi AppTec, Labcorp Drug Development and Charles River Laboratories. Direct peers are Crown Bioscience, Champions Oncology and MI Bioresearch. Emerging players are The Jackson Laboratory, Taconic Biosciences and Reaction Biology.

Does XenoSTART have an API?

No public API is recorded for XenoSTART.

What industry is XenoSTART in?

XenoSTART's product category is Preclinical Oncology CRO Services. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAGAOAJ, Preclinical, Toxicology & Translational Science Staffing FSP. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSTART Appoints Dr. Frank Smith President of its XenoSTART Preclinical Research Business UnitThe START Center for Cancer Research announced the appointment of Dr. Frank Smith as President of XenoSTART, its preclinical business unit. Dr. Smith brings operational and leadership experience from previous roles at Charles River, GSK, and Champions Oncology, and will oversee XenoSTART's operations while scaling its patient-derived xenograft (PDX) platform for oncology drug developers. The appointment aims to reinforce XenoSTART's position as a leading provider of translational research in oncology, with a focus on accelerating the translation of preclinical insights into clinical development.EIN PresswirePatient-Derived Xenograft (PDX) Models Market Driving Precision Oncology and Translational Cancer ResearchThe global Patient-Derived Xenograft (PDX) Models Market is projected to grow during the forecast period, driven by increasing oncology drug pipelines, rising cancer prevalence, and expanding R&D investments by pharmaceutical and biotechnology companies. Recent market developments include Crown Bioscience opening a Model Development Center in North Carolina, Charles River Laboratories completing the acquisition of Oncodesign, Thermo Fisher Scientific acquiring Cognate BioServices, and multiple strategic collaborations such as XenoSTART with Minerva Imaging and Crown Bioscience with Jiangsu Hengrui Medicine. North America currently dominates the market while the Asia-Pacific region is emerging as the fastest-growing market.PR NewswireXenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development PlatformXenoSTART and Minerva Imaging expanded their decade-long partnership to create an integrated platform for radiopharmaceutical drug development, combining XenoSTART's clinically annotated patient-derived xenograft models with Minerva Imaging's imaging and manufacturing capabilities. The collaboration aims to accelerate discovery and reduce risk in oncology, particularly for prostate cancer.YahooXenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development PlatformXenoSTART and Minerva Imaging expanded their decade-long partnership to create an integrated platform for radiopharmaceutical drug development, combining XenoSTART's clinically annotated patient-derived xenograft models with Minerva Imaging's imaging and manufacturing capabilities. The collaboration aims to accelerate discovery and reduce risk in oncology, particularly for prostate cancer.Business Wire BlogKiyatec and XenoSTART formally announce a collaborative agreement to help reduce drug development costs by providing correlative ex vivo efficacy data using Kiyatec’s 3D spheroid screening platform, KKiyatec and XenoSTART announced a collaboration to use Kiyatec's ex vivo 3D spheroid platform with XenoSTART's XPDX models to reduce drug development costs. The companies will present data at the Tumor Models Summit in Boston on July 12, 2023.